UK Markets closed

Natera, Inc. (NTRA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
52.87-2.30 (-4.17%)
At close: 4:00PM EDT

Natera, Inc.

201 Industrial Road
Suite 410
San Carlos, CA 94070
United States
650 249 9090
http://www.natera.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full-time employees1,039

Key executives

NameTitlePayExercisedYear born
Dr. Matthew RabinowitzCo-Founder & Exec. Chairman497.18k7.06M1973
Mr. Steve ChapmanCEO, Pres & Director680.92k2.07M1979
Mr. Jonathan SheenaCo-Founder, Chief Technology Officer & Director297.13k15.12M1973
Mr. Michael BrophyChief Financial Officer521.62k1.36M1980
Mr. Robert A. SchuerenChief Operating Officer626.18kN/A1962
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Natera, Inc. provides preconception and prenatal genetic testing services. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora products of conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Evercord, a cord blood and cord tissue processing and storage service; and Signatera, a circulating tumor DNA technology that analyzes and tracks mutations to an individual's tumor. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners in the United States and internationally. Natera, Inc. has research collaborations with the Institut Jules Bordet and Fox Chase Cancer Center; and a partnership agreement with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays for use by biopharmaceutical and clinical customers. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.

Corporate governance

Natera, Inc.’s ISS governance QualityScore as of 8 December 2019 is 9. The pillar scores are Audit: 2; Board: 10; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.
By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more